The emergence of resistant strains necessitates a reevaluation of toxicological assessments for antimicrobial agents. The efficacy of antibiotics is a critical component of their risk assessment, and resistance diminishes this efficacy, potentially altering the risk-benefit ratio. Moreover, resistant infections may require higher doses or combination therapies, increasing the risk of adverse effects and toxicity.
